Literature DB >> 25654275

Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors.

Adam J Guenzel1, Renata Collard, Jan P Kraus, Dietrich Matern, Michael A Barry.   

Abstract

Propionic academia (PA) occurs because of mutations in the PCCA or PCCB genes encoding the two subunits of propionyl-CoA carboxylase, a pivotal enzyme in the breakdown of certain amino acids and odd-chain fatty acids. There is no cure for PA, but dietary protein restriction and liver transplantation can attenuate its symptoms. We show here that a single intravenous injection of adeno-associated virus 2/8 (AAV8) or AAVrh10 expressing PCCA into PA hypomorphic mice decreased systemic propionylcarnitine and methyl citrate for up to 1.5 years. However, long-term phenotypic correction was always better in male mice. AAV-mediated PCCA expression was similar in most tissues in males and females at early time points and differed only in the liver. Over 1.5 years, luciferase and PCCA expression remained elevated in cardiac tissue for both sexes. In contrast, transgene expression in the liver and skeletal muscles of female, but not male, mice waned—suggesting that these tissues were major sinks for systemic phenotypic correction. These data indicate that single systemic intravenous therapy by AAV vectors can mediate long-term phenotype correction for PA. However, tissue-specific loss of expression in females reduces efficacy when compared with males. Whether similar sex-biased AAV effects occur in human gene therapy remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25654275      PMCID: PMC4367234          DOI: 10.1089/hum.2014.126

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  44 in total

1.  Living-related liver transplantation for neonatal-onset propionic acidemia.

Authors:  T Yorifuji; J Muroi; A Uematsu; T Nakahata; H Egawa; K Tanaka
Journal:  J Pediatr       Date:  2000-10       Impact factor: 4.406

2.  Mutation analysis in 54 propionic acidemia patients.

Authors:  J P Kraus; E Spector; S Venezia; P Estes; P W Chiang; G Creadon-Swindell; S Müllerleile; L de Silva; M Barth; M Walter; K Walter; T Meissner; M Lindner; R Ensenauer; R Santer; O A Bodamer; M R Baumgartner; M Brunner-Krainz; D Karall; C Haase; I Knerr; T Marquardt; J B Hennermann; R Steinfeld; S Beblo; H G Koch; V Konstantopoulou; S Scholl-Bürgi; A van Teeffelen-Heithoff; T Suormala; M Ugarte; W Sperl; A Superti-Furga; K O Schwab; S C Grünert; J O Sass
Journal:  J Inherit Metab Dis       Date:  2011-10-27       Impact factor: 4.982

3.  Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture.

Authors:  G Touati; V Valayannopoulos; K Mention; P de Lonlay; P Jouvet; E Depondt; M Assoun; J C Souberbielle; D Rabier; H Ogier de Baulny; J-M Saudubray
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

4.  Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation.

Authors:  Allison P Dane; Sharon C Cunningham; Nicole S Graf; Ian E Alexander
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

5.  Auxiliary liver transplantation for metabolic diseases.

Authors:  M Rela; P Muiesan; P Andreani; P Gibbs; G Mieli-Vergani; A P Mowat; N D Heaton
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

6.  Secondary mitochondrial dysfunction in propionic aciduria: a pathogenic role for endogenous mitochondrial toxins.

Authors:  Marina A Schwab; Sven W Sauer; Jürgen G Okun; Leo G J Nijtmans; Richard J T Rodenburg; Lambert P van den Heuvel; Stefan Dröse; Ulrich Brandt; Georg F Hoffmann; Henk Ter Laak; Stefan Kölker; Jan A M Smeitink
Journal:  Biochem J       Date:  2006-08-15       Impact factor: 3.857

7.  Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review.

Authors:  Neal R Barshes; Jason M Vanatta; Akash J Patel; Beth A Carter; Christine A O'Mahony; Saul J Karpen; John A Goss
Journal:  Pediatr Transplant       Date:  2006-11

8.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

9.  N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers.

Authors:  Mendel Tuchman; Ljubica Caldovic; Yevgeny Daikhin; Oksana Horyn; Ilana Nissim; Itzhak Nissim; Mark Korson; Barbara Burton; Marc Yudkoff
Journal:  Pediatr Res       Date:  2008-08       Impact factor: 3.756

10.  Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy.

Authors:  Sean E Hofherr; Julien S Senac; Christopher Y Chen; Donna J Palmer; Philip Ng; Michael A Barry
Journal:  Hum Gene Ther       Date:  2009-02       Impact factor: 5.695

View more
  12 in total

1.  Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep.

Authors:  Amira D Rghei; Laura P van Lieshout; Wenguang Cao; Shihua He; Kevin Tierney; Jordyn A Lopes; Nicole Zielinska; Enzo M Baracuhy; Elena S B Campbell; Jessica A Minott; Matthew M Guilleman; Pamela C Hasson; Brad Thompson; Khalil Karimi; Byram W Bridle; Leonardo Susta; Xiangguo Qiu; Logan Banadyga; Sarah K Wootton
Journal:  Gene Ther       Date:  2022-09-01       Impact factor: 4.184

2.  Import of TAT-Conjugated Propionyl Coenzyme A Carboxylase Using Models of Propionic Acidemia.

Authors:  Renata Collard; Tomas Majtan; Insun Park; Jan P Kraus
Journal:  Mol Cell Biol       Date:  2018-02-27       Impact factor: 4.272

3.  AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.

Authors:  Lili Wang; Peter Bell; Hiroki Morizono; Zhenning He; Elena Pumbo; Hongwei Yu; John White; Mark L Batshaw; James M Wilson
Journal:  Mol Genet Metab       Date:  2017-03-02       Impact factor: 4.797

4.  AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice.

Authors:  Aimee E Vozenilek; Cassidy M R Blackburn; Robert M Schilke; Sunitha Chandran; Reneau Castore; Ronald L Klein; Matthew D Woolard
Journal:  Atherosclerosis       Date:  2018-09-08       Impact factor: 5.162

5.  Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.

Authors:  Amine Meliani; Florence Boisgerault; Zachary Fitzpatrick; Solenne Marmier; Christian Leborgne; Fanny Collaud; Marcelo Simon Sola; Severine Charles; Giuseppe Ronzitti; Alban Vignaud; Laetitia van Wittenberghe; Beatrice Marolleau; Fabienne Jouen; Sisareuth Tan; Olivier Boyer; Olivier Christophe; Alain R Brisson; Casey A Maguire; Federico Mingozzi
Journal:  Blood Adv       Date:  2017-10-16

6.  Pantothenate kinase activation relieves coenzyme A sequestration and improves mitochondrial function in mice with propionic acidemia.

Authors:  Chitra Subramanian; Matthew W Frank; Rajendra Tangallapally; Mi-Kyung Yun; Anne Edwards; Stephen W White; Richard E Lee; Charles O Rock; Suzanne Jackowski
Journal:  Sci Transl Med       Date:  2021-09-15       Impact factor: 17.956

7.  Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State.

Authors:  Georgios Louloudis; Samuele Ambrosini; Francesco Paneni; Giovanni G Camici; Dietmar Benke; Jan Klohs
Journal:  Front Cardiovasc Med       Date:  2021-09-22

8.  AAV-mediated BMP7 gene therapy counteracts insulin resistance and obesity.

Authors:  Estefania Casana; Veronica Jimenez; Claudia Jambrina; Victor Sacristan; Sergio Muñoz; Jordi Rodo; Ignasi Grass; Miquel Garcia; Cristina Mallol; Xavier León; Alba Casellas; Víctor Sánchez; Sylvie Franckhauser; Tura Ferré; Sara Marcó; Fatima Bosch
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-16       Impact factor: 6.698

9.  Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia.

Authors:  Lili Wang; Ilayaraja Muthuramu; Suryanarayan Somanathan; Hong Zhang; Peter Bell; Zhenning He; Hongwei Yu; Yanqing Zhu; Anna P Tretiakova; James M Wilson
Journal:  Mol Ther Methods Clin Dev       Date:  2021-05-05       Impact factor: 6.698

Review 10.  The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Genes (Basel)       Date:  2020-08-10       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.